FDA to decide on Brilinta by July
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.US regulators have set a deadline of 20 July for deciding whether to give the go-ahead to Brilinta, AstraZeneca's new heart drug.
Astra's shares were hit in December when it revealed that the US Food and Drug Administration had failed to approve the new treatment.
Yesterday, the pharmaceuticals giant said that, instead of opting for a shorter, two-month delay, the FDA had gone for a longer review, pushing Brilinta's US launch to the second half of the year. The drug, a blood thinner, is the UK group's answer to Plavix, which is manufactured by Sanofi-Aventis and Bristol-Myers Squibb and is the world's second-biggest-selling drug, with sales of more than $9bn (£5.6bn) a year.
Brilinta has already been approved in Europe, where it will be sold as Brilique.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments